Cargando…
P401: INNOVATIVE REDUCED-DOSE CHEMOTHERAPY FOLLOWED BY BLINATUMOMAB INDUCTION THERAPY FOR SUCCESSFUL MANAGEMENT OF TREATMENT NAIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ADULTS: A MULTICENTER, REAL-WORLD STUDY
Autores principales: | Lu, Jing, Zhou, Huifen, Zhou, Xin, Yang, Yonggong, Tong, Laigen, Miao, Miao, Yang, Xiaofei, Chen, Suning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429608/ http://dx.doi.org/10.1097/01.HS9.0000968512.20949.2b |
Ejemplares similares
-
Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016) -
Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019) -
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
por: Wei, Andrew H., et al.
Publicado: (2021) -
An unusual hematopoietic stem cell transplantation for donor acute lymphoblastic leukemia: a case report
por: Zhou, Di, et al.
Publicado: (2020) -
Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)